Travere Therapeutics, Inc.
Clinical trials sponsored by Travere Therapeutics, Inc., explained in plain language.
-
New drug shows promise in slowing kidney disease for FSGS patients
Disease control CompletedThis study tested a new medicine called sparsentan in 371 people with a rare kidney disease called FSGS. The goal was to see if it could slow down kidney damage better than a standard blood pressure pill. Participants took either sparsentan or the standard drug for two years, and…
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:28 UTC
-
New drug combo shows promise for slowing kidney disease
Disease control CompletedThis study tested whether adding the drug sparsentan to a standard SGLT2 inhibitor can safely reduce protein leakage in the urine of adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The 48 participants had already been on stable doses of both an SGLT…
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 18, 2026 12:10 UTC